Oncotarget

Research Papers:

Prognostic and clinicopathologic significance of SIRT1 expression in hepatocellular carcinoma

Hongyuan Jiang, Xiao Zhang, Yuquan Tao, Liang Shan, Qijun Jiang, Yongchun Yu, Feng Cai _ and Lifang Ma

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:52357-52365. https://doi.org/10.18632/oncotarget.14096

Metrics: PDF 1282 views  |   HTML 2056 views  |   ?  


Abstract

Hongyuan Jiang1,*, Xiao Zhang2,*, Yuquan Tao1, Liang Shan1, Qijun Jiang1, Yongchun Yu1, Feng Cai3 and Lifang Ma3

1Shanghai Municipal Hospital of Traditional Chinese Medicine Affiliated to Shanghai TCM University, Shanghai, 200071, China

2Department of Clinical Laboratory Medicine, Shanghai Tenth People’s Hospital of Tongji University, Shanghai, 200072, China

3Department of Clinical Laboratory Medicine, Shanghai Municipal Hospital of Traditional Chinese Medicine Affiliated to Shanghai TCM University, Shanghai, 200071, China

*These authors have contributed equally to this work

Correspondence to:

Feng Cai, email: 1182@szy.sh.cn

Lifang Ma, email: malifang0606118@126.com

Keywords: meta-analysis, prognosis, clinical value, HCC, hazard ratio

Received: September 22, 2016     Accepted: November 19, 2016     Published: December 22, 2016

ABSTRACT

The clinical value of SIRT1 in hepatocellular carcinoma (HCC) remains controversial. This meta-analysis was performed to investigate the prognostic and clinicopathological significance of the histone deacetylase SIRT1 in HCC. Pooled hazard ratios (HRs) for survival outcomes and pooled odds ratios (ORs) for clinical parameters associated with SIRT1 were calculated in nine studies using Review Manager. Meta-analysis showed that increased SIRT1 expression is associated with poor overall survival (OS) (HR=1.82, 95% confidence interval (CI): 1.49-2.22, P<0.00001) and disease-free survival (DFS) (HR=1.44, 95%CI: 1.06-1.96, P=0.02) in HCC. Increased expression of SIRT1 is more common in female than male HCC patients (OR=0.47, 95%CI: 0.32-0.70, P=0.0001). The increased SIRT1 expression correlates with hepatitis B virus (HBV) infection (OR=1.63, 95%CI: 1.04-2.57, P=0.03), large tumor size (OR=1.81, 95%CI: 1.05-3.13, P=0.03), high p53 expression (OR=2.71, 95%CI: 1.39-5.29, P=0.003), high levels of alpha-fetoprotein (AFP; cutoff value: 400 ng/ml, OR=1.84, 95%CI: 1.26-2.69, P=0.002), and tumor stage (OR=1.72, 95%CI: 1.27-2.32, P=0.0004). Re-sampling statistics for 5,000,000 samples revealed that increased SIRT1 expression is associated with higher TNM stage (OR=1.70, 95%CI: 1.69-1.70, P<0.00001). These results indicate that SIRT1 is a new biomarker off HCC as well as a potentially effective therapeutic target.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 14096